ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 746

Increased Risk of Acute and Chronic Renal Comorbidity in Ankylosing Spondylitis: Results From a Population-Based Study

Walter P. Maksymowych1, Shelagh Szabo2, Sumati Rao3, Mary A. Cifaldi3 and Adrian R. Levy4, 1Department of Medicine, University of Alberta, Edmonton, AB, Canada, 2Oxford Outcomes, Oxford Outcomes, Vancouver, BC, Canada, 3Abbott Laboratories, Abbott Park, IL, 4Oxford Outcomes Ltd, Vancouver, BC, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), comorbidity and renal disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research I: Epidemiology and Outcomes in Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Clinical evidence points to an increased risk of renal comorbidity in ankylosing spondylitis (AS) compared to the general population.  However, there are no population-based estimates available in the literature.  An increased risk of renal comorbidity would have substantial implications for the monitoring and treatment of AS because the mainstay of pharmacological treatment is the use of non-steroidal anti-inflammatory agents (NSAIDs).  We estimated the prevalence and age- and sex-standardized increased risk of renal comorbidity, including acute and chronic kidney disease and amyloidosis in a population-based cohort of persons diagnosed with AS in Québec between 1996 and 2006, compared to the general population.

Methods: A retrospective cohort study was conducted using the administrative physician-billing database of the Régie de l’Assurance Maladie du Québec. The cohort included individuals with at least one International Classification of Diseases, 9th Revision (ICD-9) billing code for AS between 1996 and 2006. A comparison cohort was generated using a 1% random sample of individuals without AS. Renal complications were identified by ICD-9 codes for amyloidosis, hypertensive chronic renal disease, acute and chronic renal disease.  Age- and sex-stratified prevalence, and standardized prevalence ratios with 95% confidence intervals (CI), of renal complications in AS compared with the general population were calculated. Sensitivity analysis was conducted using two ICD-9 codes for AS.

Results: There were 8,616 individuals identified with AS; 56% were male and the median age at diagnosis was 42 years. Overall, renal complications were diagnosed among 3.4% and 2.1% of males and females with AS, compared to 2.0% and 1.6% of males and females in the general population cohort, respectively. Prevalence of renal complications increased with age in both the AS and general population cohort. Age- and sex-stratified prevalence ratios, comparing the risk of renal complications among those with AS to the general population, demonstrated a significantly excess risk of renal complications that was highest among younger individuals with AS.  Overall, individuals with AS were at a significantly increased risk of renal complications compared to members of the general population (irrespective of a coding for hypertension), with a standardized prevalence ratio of 1.7 (1.5-2.0).  Standardized prevalence ratios were 6.0 (2.0-18.0) for amyloidosis, 1.7 (1.4-2.0) for chronic kidney disease, 3.2 (0.8 – 12.4) for hypertensive kidney disease, and 1.9 (1.5 – 2.3) for acute kidney disease. The excess risk was highest among younger individuals with AS, and results were similar when two ICD-9 codes were used to identify AS.

Conclusion: This population-based analysis shows that individuals with AS are at increased risk of many types of renal complications, including acute kidney disease, with the excess risk being greatest among younger individuals. These data highlight the importance of careful monitoring for renal complications among those with AS, particularly during long-term continuous use of NSAIDs.


Disclosure:

W. P. Maksymowych,

Abbott Laboratories,

5,

Abbott Laboratories,

2,

Abbott Laboratories,

8;

S. Szabo,

Oxford Outcomes,

3;

S. Rao,

Abbott Laboratories,

1,

Abbott Laboratories,

3;

M. A. Cifaldi,

Abbott Laboratories,

3,

Abbott Laboratories,

1;

A. R. Levy,

Abbott Laboratories,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-risk-of-acute-and-chronic-renal-comorbidity-in-ankylosing-spondylitis-results-from-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology